BioSpace

Pfizer pens $500M+ deal with Enodia to destroy disease-causing proteins

After Pfizer’s venture arm co-led Enodia Therapeutics’ $25 million seed round in January, the pharma has signed up to collaborate with the biotech on small-molecule drugs to eliminate pathogenic proteins where they’re being made.

By BioSpace

1 min read
Pfizer pens $500M+ deal with Enodia to destroy disease-causing proteins
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights